Astellas Pharma Gmbh

Telsar Pharma Inc.

Takanao Otsuka

Shigehiro Takase

Hideyuki Muramatsu

Hirotsugu Ueda

Michizane Hashimoto

Keiko Fujie

Hirotsugu c/o Astellas Pharma Inc Ueda

Michizane c/o Astellas Pharma Inc Hashimoto

Shigehiro c/o Astellas Pharma Inc Takase

Hideyuki c/o Astellas Pharma Inc Muramatsu

Keiko c/o Astellas Pharma Inc Fujie

The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging toand recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.

Compound WS 727713

The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging toand recovering the compound from a culture broth, a pharmaceutical composition containing the compound, a use of the compound for manufacture of a medicament or a cosmetic for melanocortin receptor modulation, a use of the compound for manufacture of a medicament or a cosmetic for treating or preventing ishemia/reperfusion injury, brain and renal inflammatory diseases, hepatitis, sepsis/septic shock, hypoxic shock, acute respiratory distress syndrome (ARDS), rheumatic arthritis (RA), gouty arthritis, aortic regurgitation (AR), juvenile chronic arthritis, osteoarthritis, nephritis, induction of tolerance, contact hypersensitivity, inflammatory bowel disease (IBD), sexual dysfuntion, transplantation, pain, disease progression of HIV, postinflammatory hypopigmentation, tinea versicolor, idiopathic guttate hypomelanosis, fever, functional bowel disease, obesity, satiety effect, diabetes mellitus, modulation of dermal exocrine function, canities (canities circumscripta), gray hair, pancreatitis, fibrotic disorders (hypertrophic scars, keloids, localized scleroderma, systematic sclerosis, sclerodermic graft versus host disease of the skin, cirrhosis of the liver, idiopathic and bleomycin induced lung fibrosis, cyclosporin induced nephropathy), uveitis (especially in Beh&#xe7;et's syndrome and sarcoidosis), vasculitis, microbial infections, celiac disease, vulvar vestibulitis syndrome, melonozna invasion, anorexia or the like.

The present invention relates to a compound WS727713, useful as a modulator of melanocortin receptors, and a process for its production by culturing in a culture medium thestrain of the genus, deposit number FERM BP-7570 and recovering the compound.

Compound WS727713

Growing community of inventors

Okayama, Japan

Takanao Otsuka